ATAvenzo Therapeutics, Inc.RRallybio Corporation

Overview

Rallybio Corporation agreed to acquire Avenzo Therapeutics, Inc. in an all-stock reverse-merger-style transaction, with the combined company to operate as Avenzo Therapeutics. A concurrent $215 million private placement accompanied the merger.

Deal rationale

The merger gives Rallybio stockholders exposure to Avenzo's four-program clinical oncology pipeline, and the $215 million financing is expected to fund operations into late 2028.

Timeline

1. AnnouncedJun 1, 2026

   Imported from prototype record 303, unverified

   Filing

Valuation and terms

Advisors

Parties